Cargando…

Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial

BACKGROUND: Pyronaridine-artesunate (PA) is a registered artemisinin-based combination therapy, potentially useful for mass drug administration campaigns. However, further data are needed to evaluate its efficacy, safety and tolerability as full or incomplete treatment in asymptomatic Plasmodium fal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dabira, Edgard D, Hachizovu, Sebastian, Conteh, Bakary, Mendy, Alieu, Nyang, Haddy, Lawal, Bolarinde, Ndiath, Mamadou Ousmane, Mulenga, Joyce M, Mwanza, Sydney, Borghini-Fuhrer, Isabelle, Arbe-Barnes, Sarah, Miller, Robert, Shin, Jangsik, Duparc, Stephan, D’Alessandro, Umberto, Manyando, Christine, Achan, Jane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Articles and Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800175/ https://www.ncbi.nlm.nih.gov/pubmed/33983371 http://dx.doi.org/10.1093/cid/ciab425

Ejemplares similares

Pharmacokinetic Interaction between Pyronaridine-Artesunate and Metoprolol
por: Morris, Carrie A., et al.
Publicado: (2014)

Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials
por: Duparc, Stephan, et al.
Publicado: (2013)

Drug-Drug Interaction Analysis of Pyronaridine/Artesunate and Ritonavir in Healthy Volunteers
por: Morris, Carrie A., et al.
Publicado: (2012)

Effectiveness of pyronaridine-artesunate against Plasmodium malariae, Plasmodium ovale spp, and mixed-Plasmodium infections: a post-hoc analysis of the CANTAM-Pyramax trial
por: Groger, Mirjam, et al.
Publicado: (2022)

Pyronaridine–artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: A single-arm, open-label, cohort event monitoring study
por: Tona Lutete, Gaston, et al.
Publicado: (2021)

Review of pyronaridine anti-malarial properties and product characteristics
por: Croft, Simon L, et al.
Publicado: (2012)

Efficacy and Safety of Pyronaridine–Artesunate for the Treatment of Uncomplicated Plasmodium falciparum and Plasmodium vivax Malaria in Myanmar
por: Han, Kay Thwe, et al.
Publicado: (2020)

Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial
por: Sagara, Issaka, et al.
Publicado: (2016)

Pyronaridine-Artesunate versus Chloroquine in Patients with Acute Plasmodium vivax Malaria: A Randomized, Double-Blind, Non-Inferiority Trial
por: Poravuth, Yi, et al.
Publicado: (2011)

Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients
por: Ayyoub, Amal, et al.
Publicado: (2016)

Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial
por: Kayentao, Kassoum, et al.
Publicado: (2012)

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria
por: Pryce, Joseph, et al.
Publicado: (2019)

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria
por: Pryce, Joseph, et al.
Publicado: (2022)

Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria
por: Bukirwa, Hasifa, et al.
Publicado: (2014)

Pharmacokinetic Interactions between Primaquine and Pyronaridine-Artesunate in Healthy Adult Thai Subjects
por: Jittamala, Podjanee, et al.
Publicado: (2014)

Plasmodium falciparum gametocyte dynamics after pyronaridine–artesunate or artemether–lumefantrine treatment
por: Roth, Johanna M., et al.
Publicado: (2018)

Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration
por: Morris, Carrie A, et al.
Publicado: (2011)

Efficacy and safety of pyronaridine-artesunate (Pyramax(®)) for the treatment of uncomplicated Plasmodium vivax malaria in Northwest Ethiopia
por: Mohammed, Hussein, et al.
Publicado: (2022)

Application of Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung and Trachea Exposure of Pyronaridine and Artesunate in Hamsters
por: Kang, Dong Wook, et al.
Publicado: (2023)

Efficacy and safety of pyronaridine-artesunate (PYRAMAX) for the treatment of P. falciparum uncomplicated malaria in African pregnant women (PYRAPREG): study protocol for a phase 3, non-inferiority, randomised open-label clinical trial
por: Djimde, Moussa, et al.
Publicado: (2023)

The return of chloroquine-susceptible Plasmodium falciparum malaria in Zambia
por: Mwanza, Sydney, et al.
Publicado: (2016)

Therapeutic efficacy of pyronaridine-artesunate (Pyramax(®)) against uncomplicated Plasmodium falciparum infection at Hamusit Health Centre, Northwest Ethiopia
por: Alebachew, Mihreteab, et al.
Publicado: (2023)

Prospective observational study to evaluate the clinical and biological safety profile of pyronaridine–artesunate in a rural health district in Burkina Faso
por: Rouamba, Toussaint, et al.
Publicado: (2022)

Community health workers in clinical research at the example of a phase IIIb/ IV antimalarial drug trial conducted in five African countries
por: Groger, Mirjam, et al.
Publicado: (2023)

From informed consent to adherence: factors influencing involvement in mass drug administration with ivermectin for malaria elimination in The Gambia
por: Fehr, Alexandra, et al.
Publicado: (2021)

Pyronaridine–artesunate and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial
por: Roth, Johanna M., et al.
Publicado: (2018)

Efficacy and safety of pyronaridine–artesunate versus artemether–lumefantrine in the treatment of acute uncomplicated malaria in children in South-West Nigeria: an open-labelled randomized controlled trial
por: Falade, Catherine O., et al.
Publicado: (2023)

Optimal dose finding for novel antimalarial combination therapy*
por: Duparc, S, et al.
Publicado: (2012)

Transporter Inhibition Profile for the Antivirals Tilorone, Quinacrine and Pyronaridine
por: Vignaux, Patricia A., et al.
Publicado: (2023)

Mass Drug Administration With High-Dose Ivermectin and Dihydroartemisinin-Piperaquine for Malaria Elimination in an Area of Low Transmission With High Coverage of Malaria Control Interventions: Protocol for the MASSIV Cluster Randomized Clinical Trial
por: Dabira, Edgard Diniba, et al.
Publicado: (2020)

Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso
por: Compaoré, Yves Daniel, et al.
Publicado: (2021)

Entomological impact of mass administration of ivermectin and dihydroartemisinin-piperaquine in The Gambia: a cluster-randomized controlled trial
por: Soumare, Harouna M., et al.
Publicado: (2022)

Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine
por: Pascual, Aurélie, et al.
Publicado: (2015)

Evidence for in vitro and in vivo activity of the antimalarial pyronaridine against Schistosoma
por: Koehne, Erik, et al.
Publicado: (2021)

Environmentally Responsible and Cost-Effective Synthesis of the Antimalarial Drug Pyronaridine
por: Kincaid, Joseph R. A., et al.
Publicado: (2022)

Pyronaridine: a review of its clinical pharmacology in the treatment of malaria
por: Chu, Wan-Yu, et al.
Publicado: (2023)

Plasmodium vivax in Children: Hidden Burden and Conspicuous Challenges, a Narrative Review
por: Drysdale, Myriam, et al.
Publicado: (2022)

Perceptions and acceptability of the controlled human malaria infection (CHMI) model in The Gambia: a qualitative study
por: Dabira, Edgard Diniba, et al.
Publicado: (2023)

Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine
por: Walimbwa, Stephen I., et al.
Publicado: (2019)

Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l7rm4c3t5cips1ui1e1fpmea15